title: Therapeutic perspectives for melatonin agonists and antagonists.
abstract: Melatonin is a neurohormone synthesized in the pineal gland during the dark period in all species, including humans. The diversity and differences in melatonin receptor distribution in the brain and extracerebral organs suggest multiple functional roles for melatonin. Administration of melatonin agonists reduces neophobia and treatment with a melatonin antagonist during the dark period reverses the anxiolytic-like effect of endogenous melatonin. Chronic treatment with agonists prevents various perturbations induced by chronic mild stress. Melatonin in vivo directly constricts cerebral arterioles in rats and decreases the lower limit of cerebral blood flow autoregulation, suggesting that melatonin may diminish the risk of hypoperfusion-induced cerebral ischemia. At the extracerebral level, melatonin regulates intestinal motility in rats. The intestinal postprandial motor response is shorter in the dark phase than in the light phase and this reduction is reversed in animals pretreated with a melatonin antagonist. Moreover, melatonin reduces the duration of cholecystokinin excitomotor effect. Endogenous melatonin may modulate intestinal motility to coordinate intestinal functions such as digestion and transit and control the metabolism of the animal. An adipocyte melatonin binding site may also participate in this control. Melatonin is involved in a wide range of physiological functions. The question remains as to whether evolution, adaptation and diurnal life have modified the physiological role of melatonin in humans. Moreover, the functional role of each of the receptor subtypes has to be characterized to design selective ligands to treat specific diseases.
authors.affiliation: Institut de Recherches Internationales SERVIER, 6 Place des Pléiades, 92415 Courbevoie Cedex, France. philippe.delagrange@fr.netgrs.com
authors.forename: P
authors.initials: P
authors.lastname: Delagrange
authors.forename: J
authors.initials: J
authors.lastname: Atkinson
authors.forename: J A
authors.initials: JA
authors.lastname: Boutin
authors.forename: L
authors.initials: L
authors.lastname: Casteilla
authors.forename: D
authors.initials: D
authors.lastname: Lesieur
authors.forename: R
authors.initials: R
authors.lastname: Misslin
authors.forename: S
authors.initials: S
authors.lastname: Pellissier
authors.forename: L
authors.initials: L
authors.lastname: Pénicaud
authors.forename: P
authors.initials: P
authors.lastname: Renard
mesh_terms: D000818:Animals; D001007:Anxiety / Q000378:metabolism; D001835:Body Weight / Q000502:physiology; D001921:Brain / Q000098:blood supply / Q000378:metabolism; D002560:Cerebrovascular Circulation / Q000502:physiology; D021081:Chronobiology Disorders / Q000378:metabolism; D002940:Circadian Rhythm / Q000502:physiology*; D004195:Disease Models, Animal; D004734:Energy Metabolism / Q000502:physiology; D005769:Gastrointestinal Motility / Q000502:physiology; D008550:Melatonin / Q000819:agonists / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics* / Q000502:physiology*; D051379:Mice; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D011956:Receptors, Cell Surface / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism; D044094:Receptors, Melatonin
chemical_list: D011956:Receptors, Cell Surface; D018160:Receptors, Cytoplasmic and Nuclear; D044094:Receptors, Melatonin; D008550:Melatonin